A tirzepatide 3 month supply usually means three monthly packages planned together, not one vial meant to stay open for 90 days. Brand tirzepatide may come in pens or vials packaged around four weekly doses. Promise lists its compounded injectable vial as a 30-day supply and offers a quarterly plan. The awkward part is the first few months: the prescribed amount may change as the provider learns what a person can tolerate.
That means the prescription, the physical package, and the billing cycle may all cover slightly different spans. They need to be read separately.
How a tirzepatide 3 month supply is counted
Tirzepatide is normally prescribed once a week. Twelve weekly doses cover 84 days, although pharmacies and insurance plans may call that a 90-day fill. It is ordinary calendar shorthand, not a promise that every package contains exactly 90 days of medication.
Brand packages are tied to a fixed strength. The current Zepbound label lists four-packs of single-dose pens and vials, plus multi-dose vials and KwikPens that each contain four weekly doses. A three-month brand fill may therefore involve three monthly packages, and the strengths may not all be the same during the early months.
Compounded medication is different. The pharmacy fills the provider's prescription in the concentration, volume, and number of vials written for that patient. Promise's tirzepatide product page describes each supply unit as 30 days.
| What the phrase describes | Brand tirzepatide | Compounded tirzepatide |
|---|---|---|
| Typical package unit | Four weekly doses | Pharmacy-labeled vial or vials |
| Strength | Printed on each pen, vial, or multi-dose device | Set by the prescription and pharmacy label |
| Date that matters | Manufacturer expiration and presentation-specific storage limit | Beyond-use date and first-puncture limit |
| Three-month plan | Often three monthly packages | Three 30-day supplies under the prescribed plan |
Promise dispenses tirzepatide as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor.
Dose changes make the first three months less tidy
Titration, meaning slow dose changes over time, is built into published tirzepatide protocols. The Zepbound label describes 2.5 mg weekly for the first four weeks, followed by 5 mg weekly, with later 2.5 mg increases considered only after at least four weeks at the current dose. Those are label facts, not personal instructions; the prescriber sets the actual dose.
The reason for moving slowly is practical. In SURMOUNT-1, a 2022 trial of 2,539 adults, the study included a 20-week escalation period. Stomach-related effects were the most common adverse events and happened mainly while doses were changing (Jastreboff et al., New England Journal of Medicine, 2022).
An earlier 12-week trial of 111 adults with type 2 diabetes tested several escalation patterns. Its authors found that lower starting amounts and smaller increases were associated with a more favorable side-effect pattern (Frias et al., Diabetes, Obesity and Metabolism, 2020). That study helped shape later trial schedules; it does not provide a do-it-yourself schedule.
This is why the simple arithmetic can fail. If three identical months are dispensed before the first injection, a dose change could leave medication that no longer matches the prescription. A provider may instead begin with one month, see how it goes, and write the next supply after reviewing tolerance and response. The tirzepatide dosage schedule explains the decision points in more detail.
Why one month first can be the sensible choice
A shorter first fill is not a sign that long-term treatment has been ruled out. It gives the provider a clean point to check nausea, vomiting, constipation, hydration, blood sugar medicines, and any other concern before planning more medication.
It also reduces waste if the prescription needs to be paused or changed. A new dose can mean a new concentration or a differently labeled vial. The number printed on an old syringe plan should never be assumed to carry over to a new concentration; the pharmacy's directions and the provider's prescription belong together.
Storage can be shorter than the billing period
A three-month plan does not create a three-month storage life. Brand expiration dates come from the manufacturer's testing for that exact presentation. Compounded preparations carry a beyond-use date, or BUD, which is the pharmacy-assigned last-use date for that preparation. The two terms are not interchangeable.
As of September 6, 2026, the day this article was written, the current Zepbound label is marked Revised: 8/2026. It says single-dose pens and vials stay refrigerated at 36°F to 46°F and may be kept at up to 86°F for a total of 21 days. For the brand's multi-dose vial or KwikPen, the label gives a 30-day limit after first use or four weekly doses, whichever comes first.
Those brand rules do not automatically transfer to a compounded vial. The FDA's current GLP-1 compounding page recommends that compounded multi-dose sterile vials be discarded within 28 days after the first puncture, even when medication remains. A pharmacy label may set an earlier BUD. FDA also says injectable GLP-1 medication that arrives warm or without enough refrigeration should not be used because quality may be affected.
For a multi-vial supply, the useful habit is simple: keep unopened vials under the labeled conditions, note when each vial is first punctured, and follow the earlier applicable date. How to store peptides covers travel, refrigerator placement, and temperature problems without trying to replace the pharmacy label.
How Promise's quarterly option works
Promise lists Tirzepatide as a 30-day supply and offers a quarterly billing plan. In other words, quarterly describes how three months are purchased; it does not turn one punctured vial into a 90-day vial. The promo card shows the current plan price.
The prescription still controls the dose, and the dispensing pharmacy controls the vial labels and beyond-use dates. The number of vials and the shipping cadence can depend on what is prescribed, so those details should be confirmed from the visit and dispensing information rather than guessed from the billing interval.
If three months of tirzepatide is not the right fit
Semaglutide is another GLP-1 medication, meaning it acts on a gut-hormone signal involved in appetite and blood sugar. It is not a milligram-for-milligram substitute for tirzepatide, and the two are not meant to be combined. If tolerance, availability, or the treatment plan changes, a provider can decide whether a switch makes sense.
The tirzepatide versus semaglutide comparison explains the difference without turning it into a self-directed switch.
What to confirm before choosing quarterly
The most useful questions are concrete: whether the first three months are expected to use one strength or several, how many vials will arrive, when each shipment is planned, and which date applies after a vial is punctured. That is enough to expose most misunderstandings before extra medication is sitting in the refrigerator.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If treatment is prescribed, the provider's plan and the pharmacy label—not the length of the billing cycle—tell the patient what the supply actually contains.